Orientation May Serve as New Diagnosis Criterion

Published Online: Tuesday, January 15, 2013
Follow Pharmacy_Times:
With new research proposing that memory loss is not specific to Alzheimer’s disease, authors of a recent study suggest that spatial and temporal orientation are better indicators in diagnosing Alzheimer’s disease than memory loss.

The results of the study, published in the January 2013 issue of the Journal of Alzheimer’s Disease, tested the memory and spatial and temporal orientation of a large sample of Alzheimer’s patients and healthy controls.

Participants underwent structural imaging and magnetic resonance brain imaging. Researchers compared the orientation and memory scores for participants with Alzheimer’s with the scores of patients with another neurodegenerative condition, behavioral variant frontotemporal dementia (bvFTD).

The researchers found that Alzheimer’s patients had both impaired memory and orientation, whereas bvFTD patients only had impaired memory. Analysis of brain imaging showed that memory and orientation performance were associated with different areas of the brain in Alzheimer’s patients than in bvFTD patients.

The researchers conclude that disorientation affecting the posterior hippocampus is specific to Alzheimer’s disease. They suggest that an understanding of this disorientation will allow professionals to discriminate Alzheimer’s disease from similar conditions more effectively.

For more articles in this watch, please see:
Brains of Smokers Show More Signs of Atrophy
Parkinson's Disease Patients Demonstrate High Risk for Dementia

Related Articles
Generic versions of Actavis’s Namenda treatment for moderate-to-severe Alzheimer’s dementia have been launched by Dr. Reddy's Laboratories and Mylan.
Supplementation with omega-3 fatty acids and antioxidants could potentially benefit patients in the very early stages of Alzheimer’s disease.
Errors on brief memory tests can detect Alzheimer’s disease up to 18 years before dementia onset.
Actavis’s memantine hydrochloride extended-release and donepezil hydrochloride (Namzaric) treatment for moderate to severe Alzheimer’s disease is now available for patients and health care professionals across the United States.
Latest Issues
$auto_registration$